Last edition
News about "HitGen"
BioAge Labs Initiates Phase 1 Trial of Novel NLRP3 Inhibitor BGE-102 for Obesity Treatment
BioAge Labs, a clinical-stage biotechnology company based in Emeryville, California, has announced the initiation of a Phase 1 clinical study of BGE-102, an orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for the treatment of obesity.
HitGen | 16/09/2025 | By Dineshwori
Bridge Biotherapeutics and HitGen to Advance Novel Cancer Therapeutics Program
Bridge plans to strengthen its existing oncology portfolio, which is centered on EGFR inhibitors for lung cancer treatment, through new anticancer drug candidates targeting undisclosed targets.
HitGen | 23/08/2024 | By Aishwarya | 291
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy